A Genome-Wide Methylation Study on Essential Hypertension in Young African American Males

Xiaoling Wang, Bonita Falkner, Haidong Zhu, Huidong Shi, Shaoyong Su, Xiaojing Xu, Ashok Kumar Sharma, Yanbin Dong, Frank Treiber, Bernard Gutin, Gregory Harshfield, Harold Snieder

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: There is emerging evidence from animal studies suggesting a key role for methylation in the pathogenesis of essential hypertension. However, to date, very few studies have investigated the role of methylation in the development of human hypertension, and none has taken a genome-wide approach. Based on the recent studies that highlight the involvement of inflammation in the development of hypertension, we hypothesize that changes in DNA methylation of leukocytes are involved in the pathogenesis of hypertension. Method & Results: We conducted a genome-wide methylation analysis on 8 hypertensive cases and 8 normotensive age-matched controls aged 14-23 years and performed validation of the most significant CpG sites in 2 genes in an independent sample of 36 hypertensive cases and 60 normotensive controls aged 14-30 years. Validation of the CpG sites in the SULF1 gene was further conducted in a second replication sample of 36 hypertensive cases and 34 controls aged 15.8-40 years. A CpG site in the SULF1 gene showed higher methylation levels in cases than in healthy controls in the genome-wide step (p = 6.2×10-5), which was confirmed in the validation step (p = 0.011) for subjects ≤30 years old but was not significant for subjects of all ages combined (p = 0.095). Conclusion: The identification of a difference in a blood leukocyte DNA methylation site between hypertensive cases and normotensive controls suggests that changes in DNA methylation may play an important role in the pathogenesis of hypertension. The age dependency of the effect further suggests complexity of epigenetic regulation in this age-related disease.

Original languageEnglish (US)
Article numbere53938
JournalPloS one
Volume8
Issue number1
DOIs
StatePublished - Jan 17 2013

Fingerprint

Methylation
African Americans
methylation
hypertension
DNA Methylation
Genes
Genome
Hypertension
DNA methylation
genome
pathogenesis
Leukocytes
leukocytes
Human Development
Epigenomics
genes
human development
epigenetics
Inflammation
inflammation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A Genome-Wide Methylation Study on Essential Hypertension in Young African American Males. / Wang, Xiaoling; Falkner, Bonita; Zhu, Haidong; Shi, Huidong; Su, Shaoyong; Xu, Xiaojing; Sharma, Ashok Kumar; Dong, Yanbin; Treiber, Frank; Gutin, Bernard; Harshfield, Gregory; Snieder, Harold.

In: PloS one, Vol. 8, No. 1, e53938, 17.01.2013.

Research output: Contribution to journalArticle

@article{b4aef4f8838e47fd90f07420e41a4b43,
title = "A Genome-Wide Methylation Study on Essential Hypertension in Young African American Males",
abstract = "Objective: There is emerging evidence from animal studies suggesting a key role for methylation in the pathogenesis of essential hypertension. However, to date, very few studies have investigated the role of methylation in the development of human hypertension, and none has taken a genome-wide approach. Based on the recent studies that highlight the involvement of inflammation in the development of hypertension, we hypothesize that changes in DNA methylation of leukocytes are involved in the pathogenesis of hypertension. Method & Results: We conducted a genome-wide methylation analysis on 8 hypertensive cases and 8 normotensive age-matched controls aged 14-23 years and performed validation of the most significant CpG sites in 2 genes in an independent sample of 36 hypertensive cases and 60 normotensive controls aged 14-30 years. Validation of the CpG sites in the SULF1 gene was further conducted in a second replication sample of 36 hypertensive cases and 34 controls aged 15.8-40 years. A CpG site in the SULF1 gene showed higher methylation levels in cases than in healthy controls in the genome-wide step (p = 6.2×10-5), which was confirmed in the validation step (p = 0.011) for subjects ≤30 years old but was not significant for subjects of all ages combined (p = 0.095). Conclusion: The identification of a difference in a blood leukocyte DNA methylation site between hypertensive cases and normotensive controls suggests that changes in DNA methylation may play an important role in the pathogenesis of hypertension. The age dependency of the effect further suggests complexity of epigenetic regulation in this age-related disease.",
author = "Xiaoling Wang and Bonita Falkner and Haidong Zhu and Huidong Shi and Shaoyong Su and Xiaojing Xu and Sharma, {Ashok Kumar} and Yanbin Dong and Frank Treiber and Bernard Gutin and Gregory Harshfield and Harold Snieder",
year = "2013",
month = "1",
day = "17",
doi = "10.1371/journal.pone.0053938",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - A Genome-Wide Methylation Study on Essential Hypertension in Young African American Males

AU - Wang, Xiaoling

AU - Falkner, Bonita

AU - Zhu, Haidong

AU - Shi, Huidong

AU - Su, Shaoyong

AU - Xu, Xiaojing

AU - Sharma, Ashok Kumar

AU - Dong, Yanbin

AU - Treiber, Frank

AU - Gutin, Bernard

AU - Harshfield, Gregory

AU - Snieder, Harold

PY - 2013/1/17

Y1 - 2013/1/17

N2 - Objective: There is emerging evidence from animal studies suggesting a key role for methylation in the pathogenesis of essential hypertension. However, to date, very few studies have investigated the role of methylation in the development of human hypertension, and none has taken a genome-wide approach. Based on the recent studies that highlight the involvement of inflammation in the development of hypertension, we hypothesize that changes in DNA methylation of leukocytes are involved in the pathogenesis of hypertension. Method & Results: We conducted a genome-wide methylation analysis on 8 hypertensive cases and 8 normotensive age-matched controls aged 14-23 years and performed validation of the most significant CpG sites in 2 genes in an independent sample of 36 hypertensive cases and 60 normotensive controls aged 14-30 years. Validation of the CpG sites in the SULF1 gene was further conducted in a second replication sample of 36 hypertensive cases and 34 controls aged 15.8-40 years. A CpG site in the SULF1 gene showed higher methylation levels in cases than in healthy controls in the genome-wide step (p = 6.2×10-5), which was confirmed in the validation step (p = 0.011) for subjects ≤30 years old but was not significant for subjects of all ages combined (p = 0.095). Conclusion: The identification of a difference in a blood leukocyte DNA methylation site between hypertensive cases and normotensive controls suggests that changes in DNA methylation may play an important role in the pathogenesis of hypertension. The age dependency of the effect further suggests complexity of epigenetic regulation in this age-related disease.

AB - Objective: There is emerging evidence from animal studies suggesting a key role for methylation in the pathogenesis of essential hypertension. However, to date, very few studies have investigated the role of methylation in the development of human hypertension, and none has taken a genome-wide approach. Based on the recent studies that highlight the involvement of inflammation in the development of hypertension, we hypothesize that changes in DNA methylation of leukocytes are involved in the pathogenesis of hypertension. Method & Results: We conducted a genome-wide methylation analysis on 8 hypertensive cases and 8 normotensive age-matched controls aged 14-23 years and performed validation of the most significant CpG sites in 2 genes in an independent sample of 36 hypertensive cases and 60 normotensive controls aged 14-30 years. Validation of the CpG sites in the SULF1 gene was further conducted in a second replication sample of 36 hypertensive cases and 34 controls aged 15.8-40 years. A CpG site in the SULF1 gene showed higher methylation levels in cases than in healthy controls in the genome-wide step (p = 6.2×10-5), which was confirmed in the validation step (p = 0.011) for subjects ≤30 years old but was not significant for subjects of all ages combined (p = 0.095). Conclusion: The identification of a difference in a blood leukocyte DNA methylation site between hypertensive cases and normotensive controls suggests that changes in DNA methylation may play an important role in the pathogenesis of hypertension. The age dependency of the effect further suggests complexity of epigenetic regulation in this age-related disease.

UR - http://www.scopus.com/inward/record.url?scp=84872221875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872221875&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0053938

DO - 10.1371/journal.pone.0053938

M3 - Article

C2 - 23325143

AN - SCOPUS:84872221875

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e53938

ER -